Cohort A - neoadjuvant administration of IDH305 at 550 mg BID for 6 weeks followed by
surgical resection at 6 weeks. If there is no evidence of progressive disease at 6 weeks
(clinical, radiographic or histopathologic exam), the patient will continue on IDH305 at 550
mg BID post-operatively for a maximum of 11 additional 28 day cycles. Subsequent assessment
of disease will occur every 2 months starting in Cycle 2.
Cohort B - patients who have inoperable tumors but measurable 2HG pre-treatment will be
treated with IDH305 at 550 mg BID x 6 weeks. If there is adequate sustained knockdown of 2HG
on MRS and disease is stable or improved, then the patient will continue on treatment for a
maximum of 11 additional 28 day cycles.